Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.

Yu Du,Jie Dai,Lili Mao,Xiaoting Wei,Xue Bai, Ling Chen,Jing Lin,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Bin Lian,Bixia Tang,Xuan Wang,Xieqiao Yan,Siming Li, Li Zhou,Jun Guo,Yu Chen,Lu Si

Journal of the European Academy of Dermatology and Venereology : JEADV（2023）

Cited 0|Views29
No score
Abstract
TQB2450 combined with anlotinib showed favorable tolerance and promising anti-tumor activity with a prolonged PFS compared with anti-PD1 monotherapy in patients with advanced acral melanoma.
More
Translated text
Key words
Acral melanoma,Anlotinib,Anti-PD-L1 antibody,Immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined